Establishment of new cloned enzyme donor immunoassays (CEDIA®) for haloperidol and bromperidol

Therapeutic Drug Monitoring

Volumn 26, Issue 3, 2004, Pages 336-341

  Yasui Furukori, Norio ^a   Saito, Manabu ^a,b   Furukori, Hanako ^a,c   Inoue, Yoshimasa ^d   Someya, Toshiyuki ^e   Kaneko, Sunao ^a   Tateishi, Tomonori ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Hirosaki Aiseikai Hospital   (Japan)

^c Department of Psychiatry   (Japan)

^d Mitsubishi Pharma   (Japan)

^e NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Bromperidol; CEDIA ; Haloperidol; HPLC; TDM

Indexed keywords

ALPRAZOLAM; ANTIPARKINSON AGENT; ANTIULCER AGENT; BENPERIDOL; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; BROMPERIDOL; BROTIZOLAM; CARBAMAZEPINE; CHLORPROMAZINE; DIAZEPAM; ESTAZOLAM; ETIZOLAM; FLUNITRAZEPAM; HALOPERIDOL; LAXATIVE; LEVOMEPROMAZINE; LITHIUM; NEUROLEPTIC AGENT; NITRAZEPAM; OLANZAPINE; PERPHENAZINE; QUAZEPAM; QUETIAPINE; RISPERIDONE; SPIPERONE; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALPROIC ACID; ZOTEPINE;

ACCURACY; ADULT; AGED; ARTICLE; AUTOMATION; CROSS REACTION; DRUG MONITORING; ENZYME IMMUNOASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; AUTOANALYSIS; CROSS REACTIONS; DRUG MONITORING; FEMALE; HALOPERIDOL; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA;

EID: 2542621336     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200406000-00020     Document Type: Article

References (14)

1. Centorrino F, Eakin M, Bahk WM, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry. 2002;159:1932-1935.
2. Van Putten T, Marder SR, Mintz J, et al. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry. 1992;149:500-505.
3. Poldinger W, Bures E, Haage H. Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol. Int Pharmacopsychiatry. 1977;12:184-192.
4. Malfroid M, Hens L, Roosen P, et al. Double-blind evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients. Acta Psychiatr Belg. 1978;78:147-154.
5. Woggon B. Effects and side-effects of bromperidol in comparison with other antipsychotic drugs. Acta Psychiatr Belg. 1978;78:155-172.
6. Yasui-Furukori N, Kondo T, Ishida M, et al. Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:53-57.
7. Someya T, Muratake T, Hirokane G, et al. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. J Clin Psychopharmacol. 2000;20:175-180.
8. Yasui-Furukori N, Furukori H, Saito M, et al. Poor reliability of therapeutic drug monitoring data for haloperidol and bromperidol using enzyme immunoassay Ther Drug Monit 2003;25:709-714.
9. Hikida K, Inoue Y, Miyazaki T, et al. Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography. J Chromatogr. 1989;495:227-234.
10. The American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
11. Hirokane G, Someya T, Takahashi S, et al. Interindividual variation of plasma haloperidol concentrations and the impact of concomitant medications: the analysis of therapeutic drug monitoring data. Ther Drug Monit. 1999;21:82-86.
12. Shimoda K, Someya T, Morita S, et al. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. Ther Drug Monit. 1999;21:293-296.
13. Shimoda K, Morita S, Yokono A, et al. CYP2D6* 10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients. Ther Drug Monit. 2000;22:392-396.
14. Fukuda R. Factors affecting serum haloperidol level assessed by longitudinal therapeutic monitoring. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:1299-1318.